mTOR pathway: A current, up-to-date mini-review (Review)
Author(s) -
Paul Zarogoulidis,
Sofia Lampaki,
J. Francis Turner,
Haidong Huang,
Stylianos Kakolyris,
Konstantinos Syrigos
Publication year - 2014
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2014.2608
Subject(s) - pi3k/akt/mtor pathway , rptor , cancer research , carcinogenesis , biology , mtorc2 , cell cycle , cell growth , kinase , mechanistic target of rapamycin , mtorc1 , oncogene , protein kinase a , cancer , signal transduction , microbiology and biotechnology , biochemistry , genetics
Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially identified as the cellular target of rapamycin. This kinase regulates cell growth, proliferation, motility and survival, as well as the gene transcription and protein synthesis that are activated in response to hormones, growth factors and nutrients. Results from preclinical studies have indicated that factors antagonizing the mTOR pathway exert an antitumor effect on lung cancer. Furthermore, primary clinical trials of mTOR inhibitors have demonstrated that the inhibitors may be effective against lung carcinoma. The present study explores the association between mTOR and lung carcinogenesis and describes the clinical trials of mTOR inhibitors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom